PMID- 38176304
OWN - NLM
STAT- MEDLINE
DCOM- 20240227
LR  - 20240227
IS  - 1532-3080 (Electronic)
IS  - 0960-9776 (Print)
IS  - 0960-9776 (Linking)
VI  - 73
DP  - 2024 Feb
TI  - New insights into HER2-low breast cancer brain metastasis: A retrospective 
      analysis.
PG  - 103669
LID - S0960-9776(23)00795-6 [pii]
LID - 10.1016/j.breast.2023.103669 [doi]
LID - 103669
AB  - BACKGROUND: A considerable number of patients with breast cancer will suffer from 
      brain metastasis in the advanced setting. The HER2 status serves as a significant 
      prognostic factor and the reference of applying treatment for patients with 
      breast cancer brain metastasis (BCBM). METHODS: Between January 2010 and July 
      2021, patients with BCBM who had available HER2 status were identified. The 
      patients with HER2 1+ in immunohistochemistry (IHC) or IHC 2+ and fluorescence in 
      situ hybridization (FISH) negative were categorized as HER2-low. Comparisons were 
      conducted between the HER2-low and HER2-zero population. The primary endpoint was 
      overall survival (OS) after the diagnosis of BCBM. Survival outcomes were 
      assessed using Kaplan-Meier curves with log-rank test and Cox proportional 
      hazards model. RESULTS: In this study, we analyzed 71 patients with the HER2-low 
      breast cancer subtype and 64 patients with the HER2-zero subtype. Despite the 
      limited sample size, our findings revealed a significantly better OS for patients 
      with HER2-low cancer compared to their HER2-zero counterparts (26 m vs 20 m, 
      p = 0.0017). This trend was particularly notable in the HR-negative group (26 m 
      vs 13 m, p = 0.0078), whereas no significant difference was observed among the 
      HR-positive patients. Furthermore, Cox regression analysis revealed that the 
      HER2-low status was an independent prognostic factor for better survival in the 
      HR-negative patients (p = 0.046 in multivariate analysis). CONCLUSIONS: Patients 
      diagnosed with HER2-low BCBM exhibited a more favorable prognosis than those with 
      HER2-zero BCBM, particularly within the HR-negative subgroup. The low expression 
      of HER2 is supposed to be linked to the prolonged survival of BCBM patients.
CI  - Copyright (c) 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Xu, Hangcheng
AU  - Xu H
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing, 
      100021, China.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing, 
      100021, China.
FAU - Li, Li
AU  - Li L
AD  - Department of Medical Records, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing, 
      100021, China.
FAU - Han, Yiqun
AU  - Han Y
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing, 
      100021, China.
FAU - Wu, Yun
AU  - Wu Y
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing, 
      100021, China.
FAU - Sa, Qiang
AU  - Sa Q
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing, 
      100021, China.
FAU - Xu, Binghe
AU  - Xu B
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing, 
      100021, China. Electronic address: xubingheBM@163.com.
FAU - Wang, Jiayu
AU  - Wang J
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing, 
      100021, China. Electronic address: drwangjy@126.com.
LA  - eng
PT  - Journal Article
DEP - 20240101
PL  - Netherlands
TA  - Breast
JT  - Breast (Edinburgh, Scotland)
JID - 9213011
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Breast Neoplasms/pathology
MH  - Receptor, ErbB-2/metabolism
MH  - Retrospective Studies
MH  - In Situ Hybridization, Fluorescence
MH  - Prognosis
MH  - *Brain Neoplasms/secondary
PMC - PMC10791565
OTO - NOTNLM
OT  - Brain metastasis
OT  - Breast cancer
OT  - HER2-Low
OT  - Prognosis
COIS- Declaration of competing interest The authors declare no conflict of interest.
EDAT- 2024/01/05 00:42
MHDA- 2024/02/27 06:44
PMCR- 2024/01/01
CRDT- 2024/01/04 18:13
PHST- 2023/07/07 00:00 [received]
PHST- 2023/11/17 00:00 [revised]
PHST- 2023/12/30 00:00 [accepted]
PHST- 2024/02/27 06:44 [medline]
PHST- 2024/01/05 00:42 [pubmed]
PHST- 2024/01/04 18:13 [entrez]
PHST- 2024/01/01 00:00 [pmc-release]
AID - S0960-9776(23)00795-6 [pii]
AID - 103669 [pii]
AID - 10.1016/j.breast.2023.103669 [doi]
PST - ppublish
SO  - Breast. 2024 Feb;73:103669. doi: 10.1016/j.breast.2023.103669. Epub 2024 Jan 1.